Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × Hyaluronoglucosaminidase × Clear all

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse